TECHNICAL DEVELOPMENTS: Interstitial Myocardial Fibrosis
Nacif et al phase resolution, 75%-85%; section thickness, 8 mm; 35° fl ip angle; and generalized autocalibrating partially parallel acquisition factor, two. Short-axis images acquired with the modifi ed Look Locker sequence with inversion recovery were obtained at the base, middle, and apical levels of the left ventricle. Images for T1 measurements were obtained before and after intravenous infusion of gadopentetate dimeglumine (0.15 mmol per kilogram of body weight; Bayer Healthcare Pharmaceuticals, NJ) injected as a bolus at a rate of 2 mL/sec and followed by a 20-mL saline fl ush. Postcontrast examinations with the modifi ed Look Locker sequence with inversion recovery were performed at the same positions as precontrast examinations 12 minutes after injection. ECV has been shown to be stable between 10 and 40 minutes after administration of gadopentetate dimeglumine (13) . To assess left ventricular function, steady-state free precession cine MR short-axis images were acquired with a temporal resolution of 40 msec. Phase-sensitive inversion-recovery late gadoliniumenhanced MR imaging was performed 15 minutes after injection to assess for focal myocardial scar (21) .
[AQ10]
involving the myocardium, we sought to develop a cardiac CT method with which to determine ECV fraction. We used cardiac MR imaging as the reference standard for comparison.
Materials and Methods

Study Population
This single-center study was approved by National Institutes of Health Clinical Center institutional review board. All study participants provided written informed consent and completed both cardiac CT and cardiac MR imaging studies on the same day within a 4-hour window. From August 2010 to October 2011, 28 participants were enrolled. Patients with New York Heart Association, or NYHA, grade II or greater heart failure and either left ventricular ejection fraction less than 40% or diagnosis of diastolic dysfunction and left ventricular ejection fraction greater than 50% were included, as were healthy individuals. Healthy subjects had no history of clinical cardiovascular disease. Normal left and right ventricular volumes and systolic functions were confi rmed at cardiac MR imaging. All clinical examinations and laboratory tests were performed no more than 7 days before cardiac CT (Fig 1) .
Cardiac MR Imaging Protocol
Images were obtained in all study subjects with a 3-T imager (Verio; Siemens, Erlangen, Germany) with a 32-channel cardiovascular array coil (In Vivo, Orlando, Fla). An 11-heart-beat modifi ed Look Locker sequence with inversion recovery was used for cardiac MR imaging T1 measurement, as described previously (20) . Scanning parameters were as follows: repetition time msec/ echo time msec/minimum inversion time msec, 1.9/1.0/110.0; inversion time increment, 80.0 msec; fi eld of view, 290-360 mm; readout resolution, 192;
[AQ7] [AQ8] [AQ9] F ocal myocardial scar after myocardial infarction can be readily identifi ed with cardiac magnetic resonance (MR) imaging with delayed gadolinium-enhanced techniques (1) . Cardiac MR imaging has been well validated and enables quantifi cation of myocardial scar mass in comparison with overall mass of the myocardium. Unfortunately, cardiac MR imaging is not widely available and has its own contraindications and limitations. Cardiac computed tomography (CT) is well tolerated by patients and has been validated for use in the detection of focal myocardial scar (2-6).
Diffuse interstitial myocardial fibrosis is an increasingly recognized disease process common to a variety of cardiomyopathies and heart failure. T1 mapping with contrast material-enhanced cardiac MR imaging has been developed to enable quantifi cation of diffusely abnormal myocardial signal intensity (7-12). Myocardial extracellular volume (ECV) fraction represents the equilibrium distribution of gadolinium in the blood and myocardium and is derived from T1 measurements. ECV is increased in association with diffuse myocardial fi brosis, a hallmark of pathologic remodeling (13) (14) (15) . Cardiac MR imaging T1 mapping with ECV determination has been validated in multiple conditions, including heart failure secondary to ischemic and nonischemic cardiomyopathies, aortic valve disease, and hypertrophic cardiomyopathy (7, 9, 12, (16) (17) (18) (19) .
With the increasing use of cardiac CT and because myocardial fi brosis is central to many disease processes [ 
AQ6]
Implication for Patient Care
ECV measured with cardiac CT n represents a new approach toward the clinical assessment of diffuse myocardial fi brosis.
Advances in Knowledge
We assessed myocardial fi brosis n by determining the extracellular volume (ECV) with low-radiation (,2 mSv) cardiac CT.
ECV measured with cardiac CT n shows good reproducibility and correlates well (r = 0.82) with ECV measured with T1-mapping cardiac MR imaging-determined values in both healthy subjects and patients with heart failure. 
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[AQ5] Bracco Diagnostics) at a rate of 4-5 mL/sec by using the following parameters: For subjects with a heart rate of less than 66 beats per minute, we used prospective electrocardiographic gating at 70%-80% of one R-R interval and x-ray exposure times ranging from 0.423 to 0.350 second. For subjects with a heart rate of at least 66 beats per minute, we used prospective electrocardiographic gating at 40%-80% of two R-R intervals and x-ray exposure times ranging from 0.714 second to 1.174 seconds. Additional parameters were as follows: tube voltage, 120 kV, tube current, 300-580 mA depending on body mass index and sex; gantry rotation speed, 0.35 second; section thickness, 0.5 mm; and scanning range, 128-160 mm. After a 10-minute delay, postcontrast cardiac CT was performed with parameters identical to those used for the precontrast calcium score scan.
Data Analysis
T1 maps from cardiac MR imaging data were calculated by using MRmap software (23 [AQ23] Cardiac MR imaging region of interest measurements obtained, A, before and, B, after gadolinium chelate administration and reformatted cardiac CT region of interest measurements obtained, C, before and, D, after administration of an iodinated contrast agent. For cardiac CT, the anterolateral myocardium was most reliably identifi ed before administration of an iodinated contrast agent. There, a region of interest from the anterolateral myocardium was used for attenuation measurements. A focal myocardial scar was identifi ed on delayed cardiac MR images and was not included in the region of interest. Red outline = myocardium, white circle = blood pool. (27) . Focal myocardial scar was defi ned by using MASS software (V2011-EXP; Leiden, the Netherlands) at a threshold of fi ve standard deviations above the remote myocardium. Two observers (J.J.L., M.S.N.; 1 year and 7 years of cardiovascular imaging experience, respectively) evaluated the cardiac MR imaging data and were blinded to the clinical data.
Cardiac CT data were reformatted to the short-axis plane to correspond to the cardiac MR acquisition. Myocardial and blood pool attenuation values at the base, middle, and apex were measured [AQ17] [AQ18]
This will be discussed later in this article. None of the study subjects had focal late gadolinium enhancement in the region of interest. The average of two independent measurements made by the same observer was used for analysis. The reader was blinded to the fi ndings of cardiac CT analysis. ECV fraction was calculated with the following equation: ECV = (DR1 m / DR1 b )⋅(12Hct), where R1 m is R1 in the myocardium, R1 b is R1 in the blood, Hct is the hematocrit level, and DR1 is the change in relaxivity. The change in relaxivity, (1/T1), was determined with the following equation: (1/T1) = R1 post 2R1 pre , where R1 post and R1 pre are R1 after and before gadolinium chelate administration, respectively (24-26).
[AQ16] Table 1 Participant Characteristics
Characteristic
All Subjects (n = 24) Healthy Subjects (n = 11) Subjects with Heart Failure (n = 13) P Value* Table 1 . Cardiac MR imaging data were available for analysis in 136 of 144 T1 maps at the base, middle, and apical levels on pre-and postcontrast images, yielding 65 of 72 ECV values with cardiac MR imaging. Seven ECV and before administration of iodinated contrast material, respectively. Coronary calcium score was quantifi ed by using the Agatston method (28) . Coronary calcium and CT angiographic data were analyzed by using Vitrea software, as described previously. Two observers (N.K., M.S.N.; 2 and 7 years of experience in cardiovascular imaging. respectively) evaluated the cardiac CT data and were blinded to the clinical data.
Statistical Analysis
The paired Student t test was used to determine signifi cant differences between cardiac CT and cardiac MR imaging ECV values. Linear regression analysis and Pearson correlation were also used to examine the relationship between two methods by using ECV at cardiac MR imaging as the predictor variable and ECV at cardiac CT as the dependent variable. The Bland-Altman method was used to calculate bias and limits of agreement. Inter-and intraobserver variability were assessed with Pearson correlation as the standard deviation of the difference (SDD) between two readings. The coeffi cient of variation was calculated by dividing the SDD by the average of the two readings. Coronary calcium was treated as the log of the calcium score plus one. P , .05 was considered indicative of a signifi cant difference.
Results
The average duration of the examination was 47 minutes 6 5 for cardiac MR imaging and 13 minutes 6 1.5 for cardiac CT. Four participants were excluded: Two had atrial fi brillation, one had shortness of breath, and one had a CT protocol violation. A total of 24 participants were included for analysis; 13 subjects had heart failure, and 11 were healthy. The mean age in this population was 63.2 years 6 10 (range, 45-95 years). Male subjects had a mean age of 60.7 years 6 6.4 (range, 46-72 years), and female subjects had a mean age of 66.6 years 6 13.7 (range, 45-95 years). There was no signifi cant difference between male and female groups in this study (P [AQ19] 
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Nacif et al myocardial scarring that is typically related to myocardial infarction. Recently, innovations in cardiac MR imaging technique have enabled assessment of diffuse myocardial fi brosis associated with heart failure or cardiomyopathy. By using a relatively low-radiation-dose method, ECV values for cardiac CT were shown to be comparable to those obtained with cardiac MR imaging. ECV values were elevated in subjects with heart failure; greater ECV values were associated with reduced ejection fraction and increased end-systolic and end-diastolic volumes. ECV fraction has been shown to be a reproducible and novel index with which to assess fi brosis (11, 13, (24) (25) (26) 29) . A wide range of disease conditions, including acute and chronic myocardial infarction (30, 31) , chronic aortic regurgitation (32) , heart failure (9), dilated cardiomyopathy (16) , and hypertrophic cardiomyopathy (17) have altered ECV values at cardiac MR imaging. Iles et al (9) showed abnormal diastolic function associated with increased
The correlation coeffi cients for inter-and intraobserver agreement for cardiac CT were 0.95 (12.2% SDD) and 0.98 (7.5% SDD), respectively, for myocardium density measurement and 0.99 (5.1% SDD) and 0.99 (2.8% SDD), respectively, for blood pool density measurement. For cardiac MR imaging, the correlation coeffi cients for inter-and intraobserver agreement were 0.98 (7.9% SDD) and 0.98 (7.0% SDD), respectively, for myocardium and 0.99 (4.0% SDD) and 0.99 (2.9% SDD), respectively, for blood pool relaxivity measurements. The average radiation dose was 1.98 mSv 6 0.16 (average dose-length product, 141.5 mGy ⋅ cm 6 11.7) for both baseline and delayed ECV measurements. The average radiation dose was 3.14 mSv 6 0.82 (average dose-length product, 221.1 mGy ⋅ cm 6 59.5) for cardiac CT angiography.
Discussion
Cardiac MR imaging and cardiac CT have been used to detect areas of focal ECV values showed good correlation between the two methods (r = 0.82, P , .001) (Fig 3a) . ECV values were slightly lower when measured with cardiac MR imaging as opposed to cardiac CT (28.6% 6 4.4 vs 31.6% 6 5.1, P = .03). The 95% limits of agreement between the two methods ranged from 22.82% to 8.85%. A small bias (3.01%) toward higher ECV was detected for cardiac CT (Fig 3b) . As expected, cardiac MR imaging-derived ECV was lower in the healthy group than in the heart failure group (26.6% 6 2.9 vs 30.3% 6 4.9, respectively; P = .03). For cardiac CT, ECV was also lower for the healthy subjects than for the patients with heart failure (29.3% 6 2.7 vs 33.5% 6 5.9, respectively; P = .03) (Fig 4) . End-diastolic volume, end-systolic volume, and time to peak fi lling rate (greater time to peak fi lling rate indicated diastolic dysfunction) were positively associated with ECV (P , .001 for all), while ejection fraction was inversely correlated with ECV for both cardiac MR imaging and cardiac CT (P , .05 for all; Table 2 ). collagen content. In the current study, decreased myocardial function and abnormal diastolic function were also associated with increased ECV. There were several limitations to this study. First, we included only the anterior and anterolateral segments of the myocardium in the analysis. These regions were reliably identifi ed on precontrast cardiac CT images and showed good contrast between adjacent pericardium and lung tissue. Second, cardiac CT ECV validation was based on cardiac MR imaging fi ndings rather than on histologic specimens. Subjects in this study were not eligible for tissue biopsy. In addition, premortem human data based on tissue biopsy were limited by very small tissue specimens that were subject to sampling error. However, previous studies have shown consistent histologic correlation between cardiac MR imaging-derived T1 and ECV values in both human and animal studies (9,10,25,26). The cardiac CT method we described requires additional radiation (mean, 1.9 mSv). Lower-dose cardiac CT techniques, such as iterative image reconstruction, were not available at the time of protocol development.
In conclusion, we have described the assessment of myocardial fi brosis via ECV determination with cardiac CT.
ECV measured with cardiac CT shows good reproducibility and correlates well with ECV measured with T1-mapping cardiac MR imaging-determined values, representing a potential new approach toward the clinical assessment of diffuse myocardial fi brosis. [AQ21]
